-+ 0.00%
-+ 0.00%
-+ 0.00%

Opus Genetics Says Global RDH12 Alliance Commits Up To $1.6M To Advance OPGx-RDH12 Development For RDH12-LCA Treatment

Benzinga·11/19/2026 12:09:05

The clinical program is being advanced through a strategic collaboration with the Global RDH12 Alliance, which brings together RDH12 Fund for Sight in the United States and Eyes on the Future in the United Kingdom. Established in July 2025, the collaboration combines patient advocacy, scientific expertise and development resources with the goal of accelerating progress toward a potential treatment for RDH12-LCA. Under the agreement, the Alliance committed up to $1.6 million toward the development of OPGx-RDH12, with eligible development costs reimbursed as activities are completed, subject to certain diligence obligations and milestones.